Saturday, October 26, 2019 1:04:48 AM
Many years ago IMGN had drugs called Oncolysin's, they were conjugated with blocked ricin which was a rather large molecule. The trial gave the drug to patients refractory to the SOC. The result was that while some benefit was seen, after a few doses patients became refractory to the drug. In reality there was a benefit which wasn't pursued, in becoming resistant to the Oncolysin, the cancer was found to no longer be refractory to the SOC and treatment was resumed. I don't know if this cycle could have been repeated many times, but no attempt was made to try it that way. Perhaps part of the thinking was that it wouldn't be a profitable product in this way, and the cost of such an approval would be very high.
Generally the FDA wants drugs that are better than the SOC. The idea that by attacking a cancer briefly with something different would extend the duration of successfully treating with the SOC is something that would require a totally different mindset from the FDA as well as drug developers. I'm no expert, but I suspect that alternating treatment for cancer to prevent the cancer from becoming refractory to a drug might permit treatment to be extended indefinitely. The question might be, do you wait for an indication of the cancer becoming refractory, or change the treatment on some schedule that's intended to prevent it. I don't know the answers, but like to ask such questions.
Frankly, if the FDA only approves drugs which are an improvement on the SOC, wouldn't it seem logical to remove the approval from the older product, making the new product the SOC. I'm not advocating that, I believe there are good uses for all these products, but if you agree with that, why not also approve drugs that show benefits, but don't surpass the SOC. I'd contend that these drugs too would give Doctors more tools to work with, and in some cases could prove to be the answer for certain patients. The big thing would be if cancers could be prevented from becoming refractory to one product by alternating with others, might that not become the SOC even if one product could be used substantially longer than the other.
Years ago I met a gentleman at a pancreatic cancer conference I attended because of a drug being discussed there. This man had pancreatic cancer for over 5 years without the Whipple procedure. His longevity was attributed to his Oncologist. Each time his Oncologist said he'd tried everything he could think of and couldn't stop the cancer from advancing he found a new Oncologist. He certainly didn't limit his treatment to the SOC, he'd try anything, and it was keeping him alive.
I believe that people treated for all sorts of cancers is improved because Doctors have learned to experiment more when cancers are no longer responding to the SOC. I seriously doubt that any approved product is purely used in the manner in which it was approved, I.E. with only the protocol specified in the clinical trial. If the FDA changed to approve drugs based on the idea of not doing harm, but approving drugs that achieved some benefit, I suspect patients would live much longer even if the benefit wasn't as great as the SOC.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM